- Home
- TTNP vs IXHL Comparison
TTNP vs IXHL Comparison
Compare TTNP & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- IXHL
- Stock Information
- Founded
- TTNP 1991
- IXHL 2001
- Country
- TTNP United States
- IXHL Australia
- Employees
- TTNP N/A
- IXHL N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- IXHL
- Sector
- TTNP Health Care
- IXHL
- Exchange
- TTNP Nasdaq
- IXHL Nasdaq
- Market Cap
- TTNP 3.4M
- IXHL 3.6M
- IPO Year
- TTNP 1996
- IXHL N/A
- Fundamental
- Price
- TTNP $4.65
- IXHL $0.18
- Analyst Decision
- TTNP
- IXHL
- Analyst Count
- TTNP 0
- IXHL 0
- Target Price
- TTNP N/A
- IXHL N/A
- AVG Volume (30 Days)
- TTNP 81.0K
- IXHL 146.9M
- Earning Date
- TTNP 05-14-2025
- IXHL 05-15-2025
- Dividend Yield
- TTNP N/A
- IXHL N/A
- EPS Growth
- TTNP N/A
- IXHL N/A
- EPS
- TTNP N/A
- IXHL N/A
- Revenue
- TTNP N/A
- IXHL $98,000.00
- Revenue This Year
- TTNP N/A
- IXHL $3,817.06
- Revenue Next Year
- TTNP N/A
- IXHL $66.67
- P/E Ratio
- TTNP N/A
- IXHL N/A
- Revenue Growth
- TTNP N/A
- IXHL N/A
- 52 Week Low
- TTNP $3.03
- IXHL $0.08
- 52 Week High
- TTNP $14.80
- IXHL $3.55
- Technical
- Relative Strength Index (RSI)
- TTNP 53.37
- IXHL 42.72
- Support Level
- TTNP $4.16
- IXHL $0.18
- Resistance Level
- TTNP $5.12
- IXHL $0.21
- Average True Range (ATR)
- TTNP 0.44
- IXHL 0.03
- MACD
- TTNP -0.01
- IXHL 0.01
- Stochastic Oscillator
- TTNP 51.54
- IXHL 6.64
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.